Iterum Therapeutics (ITRM)
(Delayed Data from NSDQ)
$1.54 USD
-0.13 (-7.78%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $1.52 -0.02 (-1.30%) 6:16 PM ET
2-Buy of 5 2
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ITRM 1.54 -0.13(-7.78%)
Will ITRM be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ITRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ITRM
Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up
Avalo (AVTX) Fails to Meet Goal in Asthma Study, Stock Down 89%
ITRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) to Gain DMD Drug Licensing Rights From Santhera
Beat the Market the Zacks Way: Uber, VirTra, Oracle in Focus
Baudax (BXRX) Up on New Neuromuscular Blocking Agent Study Data
Other News for ITRM
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
Iterum Therapeutics resubmits new drug application to U.S. FDA for oral sulopenem
Iterum Therapeutics resubmits NDA to U.S. FDA for oral sulopenem
PERI, ITRM and CADL among pre-market losers
Wall Street Analysts Are Bullish on Top Healthcare Picks